Andy Garner

Andy Garner is an accomplished biopharmaceutical leader with extensive experience in drug discovery and development. Currently serving as a Senior Vice President at Curie.Bio since November 2022, Garner is also a member of the IFOPA Research Committee as of February 2024. Previously, Garner held key roles at MOMA Therapeutics, including Vice President, where significant contributions were made to the company's successful Series B fundraising and the primary drug discovery program. Garner's career includes pivotal positions at Third Rock Ventures, Blueprint Medicines, ARIAD Pharmaceuticals, Novartis, AstraZeneca, and the Babraham Institute, with notable achievements such as leading the BLU-782 program licensed in a $535 million deal and co-founding the Oncology Lead Generation group at AstraZeneca. Garner earned a Ph.D. in Biochemistry from the University of Dundee.